Unsurprisingly, investors appear to be locking in profits after the extended rally in COVID-19 vaccine names considering the breathtaking rise in many of the players.
Support may be softening in the second-tier developers ahead of key data readouts from the leaders in the next 30-60 days.
Selected tickers and % off recent highs:
Pfizer (NYSE:PFE) (-1.4%)
AstraZeneca (NYSE:AZN) (-12.7%)
Sanofi (NASDAQ:SNY) (-5.5%)
Merck (NYSE:MRK) (-1.1%)
GlaxoSmithKline (NYSE:GSK) (-1.5%)
Moderna (NASDAQ:MRNA) (-26.7%)
BioNTech (NASDAQ:BNTX) (-33.6%)
Novavax (NASDAQ:NVAX) (-33.0%)
Dynavax (NASDAQ:DVAX) (-45.0%)
VBI Vaccines (NASDAQ:VBIV) (-49.6%)
IBio (NYSEMKT:IBIO) (-66.4%)
Inovio Pharmaceuticals (NASDAQ:INO) (-59.6%)
Heat Biologics (NASDAQ:HTBX) (-63.5%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.